Luca Sorrentino

Dr. Luca Sorrentino

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 July 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
LMLuca Muzio
Luca Muzio
RSRiccardo Sirtori
Riccardo Sirtori
DGDavide Gornati
Davide Gornati
SESimona Eleuteri
Simona Eleuteri
AFAndrea Fossaghi
Andrea Fossaghi
GMGianvito Martino
Gianvito Martino
Amyotrophic Lateral Sclerosis (ALS) is a fatal disease characterized by the degeneration of upper and lower motor neurons (MNs). We find a significant reduction of the retromer complex subunit VPS35 in iPSCs-derived MNs from ALS patients, in MNs from ALS post mortem explants and in MNs from SOD1G93A mice. Being the retromer involved in trafficking of hydrolases, a pathological hallmark in ALS, we design, synthesize and characterize an array of retromer stabilizers based on bis-guanylhydrazones connected by a 1,3-phenyl ring linker. We select compound 2a as a potent and bioavailable interactor of VPS35-VPS29. Indeed, while increasing retromer stability in ALS mice, compound 2a attenuates locomotion impairment and increases MNs survival. Moreover, compound 2a increases VPS35 in iPSCs-derived MNs and shows brain bioavailability. Our results clearly suggest the retromer as a valuable druggable target in ALS.

16 November 2015 in Biochemistry
Verified
Journal Article
Closed access
LSLuca Sorrentino
Luca Sorrentino
ACAlessandra Maria Calogero
Alessandra Maria Calogero
VPVittorio Pandini
Vittorio Pandini
MVMaria Antonietta Vanoni
Maria Antonietta Vanoni
ISIrina F. Sevrioukova
Irina F. Sevrioukova
AAAlessandro Aliverti
Alessandro Aliverti

1 August 2017 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
LSLuca Sorrentino
Luca Sorrentino
FCFederica Cossu
Federica Cossu
Mario MilaniMario Milani
Mario Milani
AAAlessandro Aliverti
Alessandro Aliverti
EMEloise Mastrangelo
Eloise Mastrangelo

1 October 2015 in Protein Expression and Purification
Verified
Journal Article
Closed access
GDGenny Degani
Genny Degani
MCMara Colzani
Mara Colzani
ATAlberto Tettamanzi
Alberto Tettamanzi
LSLuca Sorrentino
Luca Sorrentino
AAAlessandro Aliverti
Alessandro Aliverti
Laura PopoloLaura Popolo
Laura Popolo

1 June 2021 in European Journal of Organic Chemistry
Verified
Journal Article
Open access
PDF file
MCMonica Civera
Monica Civera
EMElisabetta Moroni
Elisabetta Moroni
LSLuca Sorrentino
Luca Sorrentino
FVFrancesca Vasile
Francesca Vasile
SSSara Sattin
Sara Sattin
Allosteric regulation, i. e. the control exerted on an orthosteric site by an effector interacting at a distinct and distant site, represents a prime example of a precise tuning system of several key biological processes like gene transcription, cell adhesion and, most importantly, signal transduction. Since its discovery sixty years ago, the molecular mechanisms underlying this phenomenon have been extensively investigated. The aim of this minireview is to introduce the reader to the topic of protein allostery. In particular, we briefly overview the allosteric models postulated over the years and we describe the most relevant chemical and biophysical approaches reported so far for the identification of putative allosteric sites and/or for the investigation of allosteric signal propagation throughout the protein. An outlook of the main computational and experimental methods is followed by four case studies representative of different proteins classes: enzymes, hub proteins, cell receptors, and intrinsically disordered proteins.

12 April 2019 in ChemistryOpen
Verified
Journal Article
Open access
PDF file
LSLuca Sorrentino
Luca Sorrentino
FCFederica Cossu
Federica Cossu
Mario MilaniMario Milani
Mario Milani
BMBilge Malkoc
Bilge Malkoc
WHWen‐Chieh Huang
Wen‐Chieh Huang
EMEloise Mastrangelo
Eloise Mastrangelo
Inhibitors of Apoptosis Proteins (IAPs) are conserved E3‐ligases that ubiquitylate substrates to prevent apoptosis and activate the NF‐kB survival pathway, often deregulated in cancer. IAPs‐mediated regulation of NF‐kB signaling is based on the formation of protein complexes by their type‐I BIR domains. The XIAP‐BIR1 domain dimerizes to bind two TAB1 monomers, leading to downstream NF‐kB activation. Thus, impairment of XIAP‐BIR1 dimerization could represent a novel strategy to hamper cell survival in cancer. To this aim, we previously reported NF023 as a potential inhibitor of XIAP‐BIR1 dimerization. Here we present a thorough analysis of NF023 binding to XIAP‐BIR1 through biochemical, biophysical and structural data. The results obtained indicate that XIAP‐BIR1 dimerization interface is involved in NF023 binding, and that NF023 overall symmetry and the chemical features of its central moiety are essential for an efficient interaction with the protein. Such strategy provides original hints for the development of novel BIR1‐specific compounds as pro‐apoptotic agents.